New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
09:28 EDTRPRXRepros granted end of Phase 2 meeting in late May for Proellex-V by FDA
Repros Therapeutics announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application. Once the meeting is held, the company will report the outcome to the financial community in a timely fashion.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
12:46 EDTRPRXRepros Therapeutics volatility at low end of six-month range
Repros Therapeutics overall option implied volatility of 102 compares to its 26-week average of 111 according to Track Data, suggesting decreasing price movement.
November 13, 2014
10:44 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
November 12, 2014
10:34 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI RPRX KATE PNK CZR KING TSLA UBNT LOCO GNRC
November 11, 2014
10:39 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
November 10, 2014
10:17 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:04 EDTRPRXRepros Therapeutics reports Q3 EPS 32c, consensus (39c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use